How to Source Non-IMP Supplies for Clinical Trials

Tim Holmes, Manager, Clinical Oversight of Supplies, Biogen, offers considerations on how to obtain non-IMP supplies for clinical trials

GDPR: The Implications for Clinical Development

Eight months in, Nigel Hughes, Scientific Director JCI-PDR, Janssen, examines the ramifications of GDPR on the industry now the regulation…

Industry Viewpoints: Patient Recruitment and Expanded Access

In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges of patient recruitment

Managing Blinding Requirements in IRT: An Overview

Francesco Spoto, Clinical Project Manager, explores the opportunities of using IRT solutions to manage blinded information in clinical trials

Industry Viewpoints: Clinical Trials in Asia – Key Considerations

Mainfong Ang, Amgen, sits down with CTA’s Jisong Seo about the difficulties of clinical operations in Asia

Observations from GCP Sponsor Inspections

Kevin Anderson, Director, Global Clinical Operations, Alexion Pharmaceuticals, offers a perspective on what he has observed in various GCP inspections

Is the GAIN Act Stimulating Antibiotic R&D?

Christopher J. Pace, PhD, Director of Infectious Diseases, GlobalData, assesses the impact of the GAIN Act

Strategic Comparator Sourcing – A Matter of High Priority

Ian Hoban, Pilatus Comparator Solutions, poses some key questions that should be front of mind and considered early on in…